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heBACKGROUND The recommended doses for direct oral anticoagulants (DOACs) to prevent stroke and systemic
embolism (SE) in patients with atrial fibrillation (AF) are described in specific regulatory authority approvals.
OBJECTIVES The impact of DOAC dosing, according to the recommended guidance on all-cause mortality, stroke/SE,
and major bleeding, was assessed at 2-year follow-up in patients with newly diagnosed AF.
METHODS Of a total of 34,926 patients enrolled (2013 to 2016) in the prospective GARFIELD-AF (Global Anticoagulant
Registry in the FIELD-AF), 10,426 patients received a DOAC.
RESULTS The majority of patients (72.9%) received recommended dosing, 23.2% were underdosed, and 3.8% were
overdosed. Nonrecommended dosing (underdosage and overdosage combined) compared with recommended dosing was
associated with a higher risk of all-cause mortality (hazard ratio [HR]: 1.24; 95% confidence interval [CI]: 1.04 to 1.48);
HR: 1.25 (95% CI: 1.04 to 1.50) for underdosing, and HR: 1.19 (95% CI: 0.83 to 1.71) for overdosing. The excess deaths
were cardiovascular including heart failure and myocardial infarction. The risks of stroke/SE and major bleeding were not
significantly different irrespective of the level of dosing, although underdosed patients had a significantly lower risk of
bleeding. A nonsignificant trend to higher risks of stroke/SE (HR: 1.51; 95% CI: 0.79 to 2.91) and major bleeding (HR: 1.29;
95% CI: 0.59 to 2.78) was observed in patients with overdosing.
CONCLUSIONS In GARFIELD-AF, most patients received the recommended DOAC doses according to country-specific
guidelines. Prescription of nonrecommended doses was associated with an increased risk of death, mostly cardiovascular
death, compared with patients on recommended doses, after adjusting for baseline factors. (Global Anticoagulant
Registry in the Field-AF [GARFIELD-AF]; NCT01090362) (J Am Coll Cardiol 2020;76:1425–36) © 2020 The Authors.
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anticoagulant
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VKA = vitamin K antagonis
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1426D irect oral anticoagulants (DOACs)have been recently introduced inclinical practice for several indi-
cations including stroke prevention in AF.
They were shown to be at least as effective
as vitamin K antagonists (VKAs) for stroke
prevention in AF with lower risk of
bleeding, particularly intracranial bleeding,
without the need for blood monitoring (1).
The uptake of DOACs is growing all over
the world, particularly but not only in
Western countries. They are all approved
in most countries worldwide, but with dif-ferences in regard to regulatory authority-specific
guidance that takes into account baseline character-
istics of the patients, particularly kidney function
and/or low body weight (#60 kg), age ($80 years),
bleeding risk, and drug–drug interactions. These
country-specific guidelines vary according to the
different DOACs with anti-IIa or -Xa actions (2–4).
In this context, the rules for the correct prescrip-
tion dose may be to some extent poorly under-
stood, and may be the cause of inappropriate
dosing (either underdosing or overdosing).
tSEE PAGE 1437The aims of this analysis were to: 1) assess the
patterns of DOAC prescription as regards dosing; 2)
assess the impact of regulatory and guideline rec-
ommended versus nonrecommended DOAC dosing
on the rate of events at 2-year follow-up; and 3)
identify the predictors of underdosing in patients in
newly diagnosed AF patients from the GARFIELD-AF
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The design of the GARFIELD-AF registry was reported
previously (5,6) and is available in full in the
Supplemental Appendix. Briefly, men and women
age $18 years with AF diagnosed according to stan-
dard local procedures within the previous 6 weeks,
with at least 1 risk factor for stroke as judged by the
local investigator, and with no valvular disease were
eligible for inclusion. All data was validated inter-
nally, and 20% of all data submitted electronically
were monitored against source documentation (6). In
total 52,080 patients were enrolled prospectively and
consecutively from March 2010 to August 2016 in 35
countries, and 5 consecutive cohorts of approxi-
mately 10,000 patients with an intended 2-year
follow-up. At baseline, investigators collected data
on patient demographics, medical history, care
setting, type of AF (also collected during follow-up),
and antithrombotic treatment (VKAs, DOACs, and
antiplatelet [AP] treatment). Data on components of
the CHA2DS2-VASc and HAS-BLED risk stratification
schemes were used to assess the risks of stroke and
bleeding, retrospectively.
Clinical events were defined using previously re-
ported standardized definitions (5,6). Vascular dis-
ease included peripheral artery disease or coronary
artery disease with a history of acute coronary syn-
dromes. Chronic kidney disease was classified ac-
cording to National Kidney Foundation guidelines
into 2 groups: moderate-to-severe (stages 3 to 5), mild
(stages 1 and 2), or none (7–9). Congestive heart
failure was defined as current/prior history of
congestive heart failure or left ventricular ejectione submitted work. Dr. Fox has received grants and
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1427fraction <40%. In addition to the investigator desig-
nation of an International Society on Thrombosis and
Haemostasis bleed classification, an algorithm was
applied to verify appropriate application. Data for this
analysis were extracted from the study database on
November 19, 2018.
The rules of prescription for all 4 DOACs available
for stroke prevention in at-risk patients with non-
valvular atrial fibrillation (rivaroxaban, apixaban,
edoxaban, dabigatran) approved by the European
Medicines Agency (EMA) (2), the U.S. Food and Drug
Administration (FDA) (3), or the Japanese Pharma-
ceuticals and Medical Devices Agency (PMDA) (4)
were reviewed to define recommended dosing,
underdosing, or overdosing. These rules take into
account the baseline characteristics of the patients,
particularly kidney function, body weight, age, and
bleeding risk. In addition, regulatory authorities also
expect repeated reassessment of dose over time (2–4)
(10,11). Regarding kidney function, all rules of DOAC
prescription refer to creatinine clearance (CrCl)
except for apixaban, whose labeling refers to the
components of the CrCl equation, namely serum
creatinine, body weight, and age. In GARFIELD-AF,
neither CrCl nor serum creatinine were routinely
assessed as it is a nonintervention study. Kidney
function was reported by the investigators in the form
of stages of renal function impairment as described
by the National Kidney Foundation (7–9,12). We
therefore reviewed the rules for prescription of every
DOAC to establish a correspondence between levels of
CrCl and stages of kidney dysfunction as reported by
the investigators. This review also took into account
the additional rules for prescription based on body
weight, age, and bleeding risk as stipulated for certain
DOACs (Supplemental Table 1).
ETHICS STATEMENT. Independent ethics committee
and hospital-based Institutional Review Board ap-
provals were obtained, as necessary, for the registry
protocol. Additional approvals were obtained from
individual study sites. The registry is being conducted
in accordance with the principles of the Declaration of
Helsinki, local regulatory requirements, and the In-
ternational Conference on Harmonisation Good Phar-
macoepidemiological and Clinical Practice Guidelines.
Written informed consent was obtained from all study
participants. Confidentiality and anonymity of all
enrolled patients are maintained.
STATISTICAL ANALYSIS. Univariable results are
presented as medians with interquartile range for
continuous variables and as absolute frequencies
with percentages for categorical variables. The GAR-
FIELD scores for mortality, stroke, and bleeding werecalculated using a single-imputed dataset. The pre-
sented GARFIELD score for mortality refers to the
reduced model version because of the high missing
proportion of some variables across the groups.
Five multiple imputation datasets were generated
using multivariate imputation by chained equations.
Logistic least absolute shrinkage and selection oper-
ator regression was applied on a randomly selected
single imputed dataset to determine predictors of
nonrecommended low dosing. The linearity assump-
tion was evaluated using restricted cubic splines, and
appropriate transformations applied with linear
splines as needed. The predictors were selected
among the following variables collected at
enrollment: sex, age, ethnicity, body weight, systolic
and diastolic blood pressure, pulse, type of AF, care
setting specialty and location, congestive heart fail-
ure, acute coronary syndrome, vascular disease, ca-
rotid occlusive disease, venous thromboembolism,
prior stroke, transient ischemic attack, systemic em-
bolism (SE), bleeding, hypertension, hypercholester-
olemia, diabetes, cirrhosis, moderate-to-severe
chronic kidney disease (CKD), hyperthyroidism, hy-
pothyroidism, concomitant AP therapy, current
smoking, and heavy alcohol consumption. This se-
lection procedure was repeated not considering the
variables directly involved in the definition of non-
recommended low dosing (namely, moderate-to-
severe CKD, age, and body weight). This approach
allowed the evaluation in dosing decisions of the
relative significance of factors beyond those
described in dosing guidelines. A 30-fold cross-
validation was applied during the modeling process.
Odds ratios and corresponding 95% confidence
intervals (CIs) for the variables selected by logistic
least absolute shrinkage and selection operator
regression were computed using multivariable logis-
tic regression models. Combined estimates from 5
imputations are presented.
The time at risk for selected events was calculated
from the time of enrollment in GARFIELD-AF to the
time of the first event or 2 years, whichever occurred
first. Occurrence of major clinical outcomes, namely
all-cause mortality, stroke/SE, and major bleeding, is
described using the number of events and the event
rate (per 100 person-years) with the corresponding
95% CIs. We estimated person-year rates using a
Poisson model, with the number of events as the
dependent variable and the log of time as an offset
(i.e., a covariate with a known coefficient of 1). Only
the first occurrence of each event was included.
Unadjusted and adjusted Cox proportional hazards
models were performed to test the association of off-
label DOAC dose and outcomes. A categorical variable
TABLE 1 Baseline Characteristics by DOAC Dosing
Nonrecommended
Low Dosing
(n ¼ 2,423)
Recommended
Dosing
(n ¼ 7,603)
Nonrecommended
High Dosing
(n ¼ 400)
Sex
Male 1,192 (49.2) 4,435 (58.3) 206 (51.5)
Female 1,231 (50.8) 3,168 (41.7) 194 (48.5)
Age, yrs 77.0 (69.0–83.0) 70.0 (63.0–77.0) 75.0 (68.0–82.0)
Age, yrs
<65 405 (16.7) 2,195 (28.9) 70 (17.5)
65–69 249 (10.3) 1,427 (18.8) 40 (10.0)
70–74 375 (15.5) 1,471 (19.3) 71 (17.8)
$75 1,394 (57.5) 2,510 (33.0) 219 (54.8)
Ethnicity
Caucasian 1,114 (46.6) 5,347 (71.8) 283 (72.0)
Hispanic/Latino 117 (4.9) 252 (3.4) 17 (4.3)
Asian 1,105 (46.3) 1,694 (22.7) 83 (21.1)
Afro-Caribbean/mixed/other 51 (2.2) 154 (2.1) 10 (2.5)
Body mass index, kg/m2 25.3 (22.8–28.8) 27.4 (24.3–31.2) 27.4 (23.9–32.0)
Weight, kg 68.0 (57.0–80.0) 78.0 (67.0–91.0) 78.0 (62.0–90.0)
Systolic blood pressure, mm Hg 130.0 (120.0–142.0) 132.0 (120.0–146.0) 132.0 (120.0–146.5)
Diastolic blood pressure, mm Hg 79.0 (70.0–85.0) 80.0 (70.0–90.0) 80.0 (70.0–88.0)
Pulse, beats/min 84.0 (72.0–103.0) 85.0 (70.0–110.0) 82.5 (70.0–105.5)
Type of atrial fibrillation
Permanent 305 (12.6) 861 (11.3) 53 (13.3)
Persistent 392 (16.2) 1,322 (17.4) 72 (18.0)
Paroxysmal 919 (37.9) 2,378 (31.3) 113 (28.3)
New onset (unclassified) 807 (33.3) 3,042 (40.0) 162 (40.5)
Care setting specialty at diagnosis
Internal medicine 327 (13.5) 1,191 (15.7) 92 (23.0)
Cardiology 1,866 (77.0) 5,382 (70.8) 259 (64.8)
Neurology 22 (0.9) 105 (1.4) 3 (0.8)
Geriatrics 9 (0.4) 17 (0.2) 2 (0.5)
Primary care/general practice 199 (8.2) 908 (11.9) 44 (11.0)
Care setting location at diagnosis
Hospital 1,033 (42.6) 3,822 (50.3) 508 (52.0)
Office 1,216 (50.2) 3,016 (39.7) 156 (39.0)
Anticoagulation clinic/thrombosis center 4 (0.2) 13 (0.2) 1 (0.3)
Emergency department 170 (7.0) 752 (9.9) 35 (8.8)
Medical history
Congestive heart failure 575 (23.7) 1,510 (19.9) 117 (29.3)
Coronary artery disease 494 (20.4) 1,386 (18.2) 88 (22.0)
Acute coronary syndromes 237 (10.9) 623 (9.1) 40 (11.4)
Coronary artery bypass graft 67 (2.8) 245 (3.2) 18 (4.5)
Stenting 186 (7.7) 499 (6.6) 35 (8.8)
Vascular disease 369 (15.3) 927 (12.2) 66 (16.5)
Carotid occlusive disease 81 (3.4) 218 (2.9) 17 (4.3)
Pulmonary embolism/deep vein thrombosis 43 (1.8) 179 (2.4) 24 (6.0)
Prior systemic embolism 15 (0.6) 39 (0.5) 2 (0.5)
Prior transient ischemic attack 95 (4.0) 332 (4.4) 18 (4.5)
Prior stroke 179 (7.4) 520 (6.8) 27 (6.8)
Prior bleeding 53 (2.2) 137 (1.8) 15 (3.8)
Hypertension 1,873 (77.4) 5,803 (76.5) 327 (81.8)
Hypercholesterolemia 947 (40.1) 3,395 (45.9) 174 (45.8)
Diabetes 529 (21.8) 1,601 (21.1) 96 (24.0)
Cirrhosis 9 (0.4) 25 (0.3) 3 (0.8)
Moderate to severe CKD 172 (7.1) 652 (8.6) 270 (67.5)
Dementia 81 (3.4) 86 (1.1) 12 (3.0)
Hyperthyroidism 44 (1.8) 131 (1.7) 4 (1.0)
Hypothyroidism 145 (6.1) 463 (6.2) 33 (8.3)
Concomitant AP therapy 418 (17.6) 1,065 (14.3) 63 (16.0)
Continued on the next page
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TABLE 1 Continued
Nonrecommended
Low Dosing
(n ¼ 2,423)
Recommended
Dosing
(n ¼ 7,603)
Nonrecommended
High Dosing
(n ¼ 400)
Alcohol consumption
Abstinent 1,253 (61.6) 3,037 (47.4) 203 (59.9)
Light 588 (28.9) 2,413 (37.6) 110 (32.4)
Moderate 161 (7.9) 829 (12.9) 22 (6.5)
Heavy 31 (1.5) 131 (2.0) 4 (1.2)
Smoking status
Nonsmoker 1,487 (68.9) 4,381 (62.8) 247 (65.5)
Ex-smoker 480 (22.3) 1,817 (26.0) 99 (26.3)
Current smoker 190 (8.8) 783 (11.2) 31 (8.2)
CHA2DS2-VASc score 4.0 (3.0–5.0) 3.0 (2.0–4.0) 4.0 (3.0–5.0)
HAS-BLED score* 1.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–2.0)
GARFIELD death score† 3.3 (1.9–5.7) 2.2 (1.3–3.7) 4.7 (2.8–8.8)
GARFIELD stroke score 0.9 (0.7–1.3) 0.7 (0.6–1.0) 1.4 (1.0–2.0)
GARFIELD bleeding score 1.2 (0.8–1.5) 0.9 (0.6–1.2) 1.7 (1.1–2.3)
Values are n (%) or median (interquartile range). *The risk factor “labile INRs” is not included in the HAS-BLED score as it is not collected at baseline. As a result, the maximum
HAS-BLED score at baseline is 8 points (not 9). †GARFIELD death score is based on the “reduced model” version.
CKD ¼ chronic kidney disease; DOAC ¼ direct oral anticoagulation; GARFIELD ¼ Global Anticoagulant Registry in the FIELD-AF.
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1429for dose category with 3 levels (recommended dosing,
nonrecommended low dosing, nonrecommended
high dosing) was included in the model, with patients
receiving recommended dosing treated as the refer-
ence group. This analysis was also performed
combining nonrecommended low and high dosing
into 1 category. Hazard ratios (HRs) with 95% CIs are
presented. Multivariable models were adjusted for
clinically relevant patient characteristics. Both a
Kolmogorov-type supremum statistical test and a
graphical examination of the Schoenfeld residuals
were used to assess the proportional hazards
assumption.
Statistical analyses were conducted using R sta-
tistical software and SAS version 9.4 (SAS Institute
Inc., Cary, North Carolina).
RESULTS
This analysis involved patients from cohorts 3 to 5
only (n ¼ 34,926) as no individual drug names were
collected in the first 2 cohorts. Patients on no anti-
coagulant treatment or not treated with a DOAC
(n ¼ 23,503); with more than 1 DOAC type simulta-
neously at baseline (n ¼ 11); or with no information on
starting date, no CKD stage information, or unavai-
lable dose information (n ¼ 986) were excluded from
the analysis, leaving a total of 10,426 patients, of
whom 4,491 (43.1%) received rivaroxaban, 3,290
(31.6%) apixaban, 2,359 (22.6%) dabigatran, and 286
(2.7%) edoxaban.
BASELINE CHARACTERISTICS. The majority of pa-
tients (n ¼ 7,603; 72.9%) received the recommendeddosing, 2,423 (23.2%) were underdosed, and 400
(3.8%) were overdosed. Compared with patients who
received recommended doses, patients with non-
recommended doses were more likely to be women;
more likely to be older; more likely to have higher
CHA2DS2-VASc and GARFIELD-AF scores for the risks
of death, stroke/SE, and bleeding; and were more
prone to abstain from alcohol and to be nonsmokers.
The rates of nonrecommended doses increased with
increasing CHA2DS2-VASc score, indicating that the
highest-risk patients were more prone to receive a
wrong dose of DOACs (Supplemental Figure 1).
Underdosed patients were more likely to be Asians,
to have a lower body weight, to more often expe-
rience dementia, to have the paroxysmal form of
AF, and to be taken care by a cardiologist and in an
office setting than patients of the other 2 sub-
groups. Overdosed patients were more likely to
have moderate-to-severe renal impairment (67.5%)
and a higher HAS-BLED score than patients in the
other 2 subgroups (Table 1).
PATTERNS OF DOSING. Recommended dosing was
in the range of 70.1% to 81.9% for rivaroxaban, dabi-
gatran, and apixaban, but was much lower for edox-
aban (40.6%), which was prescribed in only 286
patients (mostly in Japan). Underdosage affected
15.8% to 28.7% of patients for rivaroxaban, dabiga-
tran, and apixaban, but at a much higher rate for
edoxaban (55.9%). Last, overdosage rates were low,
from 1.3% with dabigatran to 6.5% with rivaroxaban
(Figure 1). Among patients with overdosage, 67.5%
had moderate-to-severe CKD as opposed to 8.6% of
FIGURE 2 DOAC Dosing Distribution by Country
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FIGURE 1 DOAC Dosing Prescribed at Diagnosis
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Dosing proportions are calculated for each treatment and among patients with available information to define dosing appropriateness. The
number of patients who received each treatment is reported under the treatment name. DOAC ¼ direct oral anticoagulation.
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TABLE 2 Event Rates (per 100 Person-Years) and Unadjusted and Adjusted* HRs at 2 Years After Enrollment by Dosing
Outcome Dosing Events Rate (95% CI) Unadjusted HR (95% CI) Adjusted HR (95% CI)
All-cause mortality Recommended dosing 360 2.5 (2.2–2.7) 1.00 (ref) 1.00 (ref)
Nonrecommended low dosing 195 4.2 (3.7–4.9) 1.74 (1.46–2.07) 1.25 (1.04–1.50)
Nonrecommended high dosing 33 4.4 (3.1–6.1) 1.79 (1.25–2.55) 1.19 (0.83–1.71)
Nonrecommended dosing 228 4.3 (3.7–4.9) 1.74 (1.48–2.06) 1.24 (1.04–1.48)
Stroke/SE Recommended dosing 102 0.7 (0.6–0.9) 1.00 (ref) 1.00 (ref)
Nonrecommended low dosing 39 0.9 (0.6–1.2) 1.22 (0.84–1.77) 0.92 (0.62–1.37)
Nonrecommended high dosing 10 1.3 (0.7–2.5) 1.91 (1.00–3.65) 1.51 (0.79–2.91)
Nonrecommended dosing 49 0.9 (0.7–1.2) 1.32 (0.94–1.85) 1.01 (0.70–1.45)
Major bleeding Recommended dosing 82 0.6 (0.5–0.7) 1.00 (ref) 1.00 (ref)
Nonrecommended low dosing 15 0.3 (0.2–0.5) 0.58 (0.34–1.01) 0.50 (0.28–0.88)
Nonrecommended high dosing 7 0.9 (0.5–2.0) 1.66 (0.77–3.59) 1.29 (0.59–2.78)
Nonrecommended dosing 22 0.4 (0.3–0.6) 0.74 (0.46–1.18) 0.62 (0.38–1.02)
*Hazard ratios (HRs) were adjusted for age, sex, ethnicity, type of atrial fibrillation, diabetes, hypertension, history of bleeding, prior stroke/transient ischemic attack/systemic
embolism (SE), congestive heart failure, vascular disease, smoking, and heavy alcohol consumption.
CI ¼ confidence interval.
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1431patients with recommended dosing and 7.1% of pa-
tients with underdosing (Table 1).
The nonrecommended low-dose prescription rate
was highly variable worldwide. It was <20% in most
European countries, United States, Canada,
Argentina, Australia, and South Africa; 20% to 30% in
France, Germany, Spain, and Egypt; 30% to 40% in
Brazil, Chile, Thailand, South Korea, and Japan; and
>40% in Mexico, the Middle East, India, and China. In
9 countries, the number of patients was too low
(n ¼ <100) to derive meaningful information
(Figure 2, Supplemental Figure 2).
OUTCOMES. More events occurred in patients with
nonrecommended doses compared with patients with
recommended doses. All-cause death and stroke/SE
rates were higher in nonrecommended doses, both
underdosed and overdosed patients, than in patients
receiving recommended doses. The rates of bleeding
were lower in underdosed patients, and higher in
overdosed patients compared with patients treated
with the recommended doses (Table 2).
After adjustment, the risk of all-cause death was
significantly higher in patients given non-
recommended doses overall and in underdosed pa-
tients compared with patients treated with the
recommended doses. The risk of major bleeding in
underdosed patients was lower than in appropriately
dosed patients (HR: 0.50; 95% CI: 0.28 to 0.88)
(Table 2, Central Illustration). The excess of all-cause
death was mostly due to numerically higher rates of
cardiovascular death (congestive heart failure and
myocardial infarction) in underdosed patients
compared with the recommended dosing subgroup
(Table 3). There was no excess in the rates of stroke-related death. The limited number of events in
overdosed patients prevents from deriving meaning-
ful conclusions.
PREDICTORS OF UNDERDOSING. This analysis was
carried out only in underdosed patients. Two models
were used, the first including the baseline charac-
teristics after which recommended dosing was
defined. The second model excluded these baseline
characteristics. The most potent predictors of
underdosage were female sex, non-Caucasian
ethnicity, acute coronary syndrome, vascular dis-
ease, prior stroke, diabetes, and concomitant AP
therapy. The variables used to define underdosing,
namely age, weight, and moderate-to-severe CKD,
were found to be strong predictors. When these
variables were removed from the automatic selec-
tion procedure, congestive heart failure, manage-
ment in office or anticoagulant clinics, and diastolic
blood pressure also emerged as significant (Table 4,
Figure 3, Supplemental Table 2).
DISCUSSION
The main findings of this study are that DOACs were
appropriately dosed in most patients to whom they
were prescribed with wide variations between coun-
tries, but that underdosage was not uncommon in the
range of 25%, and overdosage was rare. Use of non-
recommended doses of DOACs had an impact on
outcomes. After adjustment, nonrecommended doses
overall and underdosage were associated with a
higher risk of all-cause mortality, but with no signif-
icantly higher risk of stroke/SE. As expected, a
significantly lower risk of bleeding was associated
with underdosing. The excess of death was mostly
CENTRAL ILLUSTRATION Unadjusted and Adjusted Hazard Ratios at 2 Years After Enrollment
by Direct Oral Anticoagulant Dosing
Stroke/SE
Major Bleeding
AII-Cause Mortality
Nonrecommended Dosing
Nonrecommended High Dosing
Nonrecommended Low Dosing
Nonrecommended Dosing
Nonrecommended High Dosing
Nonrecommended Low Dosing
Nonrecommended Dosing
Nonrecommended High Dosing
Nonrecommended Low Dosing
0.25 5.03.02.01.51.00.5
Hazard Ratio
(Ref. Recommended Dosing)
Unadjusted Adjusted
Camm, A.J. et al. J Am Coll Cardiol. 2020;76(12):1425–36.
The reference category is patients prescribed with the recommended dosing at enrollment. Hazard ratios were adjusted for age, sex,
ethnicity, type of AF, diabetes, hypertension, history of bleeding, prior stroke/TIA/SE, congestive heart failure, vascular disease, smoking,
and heavy alcohol consumption. AF ¼ atrial fibrillation; SE ¼ systemic embolism; TIA ¼ transient ischemic attack.
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1432linked to numerically higher rates of cardiovascular
death, including congestive heart failure and
myocardial infarction. Overdosage was associated
with a nonsignificant trend to higher risk of all-cause
death, stroke/SE, and bleeding. The number of pa-
tients with overdosage was not large enough to derive
meaningful conclusions.
The uptake of DOACs for the prevention of stroke
in patients with AF at risk is rapidly growing world-
wide but with large variations depending mostly, but
not only, on the socioeconomic status of the countries
under consideration (13,14). This has resulted in an
increase in the rates of at-risk patients receiving
guideline-recommended anticoagulant therapy
(15,16). Kidney function, age, and body weight are
important characteristics to take into account when
deciding the dose of DOACs. This is reflected in the
Summaries of Product Characteristics (SPC)/drug la-
bels that differ for each DOAC and vary according to
regulatory agencies, EMA (2), FDA (3), or PMDA (4), as
each of them has issued different SPCs for the 4
different DOACs (2–4). This is a limiting factor for the
prescription and a source of confusion over the rulesof prescription even though there has been an
attempt to clarify them in European consensus doc-
uments (17,18). Therefore, there was a need to assess
the patterns of DOAC dose prescription, and to assess
the impact of recommended versus non-
recommended DOAC dosing on outcomes.
Underdosing in over 30% of patients was observed
in all LATAM (Latin America) countries except
Argentina, and in all Asian countries except
Singapore. Uptake of anticoagulants in stroke pre-
vention is low in LATAM countries (16,19,20).
Underdosing of VKAs prescribed for stroke preven-
tion in AF is common in Asia (10,21–23) where lighter
anticoagulation (lower target international normal-
ized ratio) was shown to be associated with less risk
of bleeding and no higher risk of stroke/SE than in
non-Asian countries (23,24). In J-ROCKET AF (Japa-
nese Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial
Fibrillation), low doses of rivaroxaban were shown to
be noninferior to dose-adjusted VKA therapy on the
efficacy composite endpoint of death and/or stroke or
TABLE 3 Distribution* of Causes of Death Among Patients Deceased Within the
First 2 Years After Atrial Fibrillation Diagnosis by Dosing
Cause of Death
Nonrecommended
Low Dosing
(n ¼ 195 Deaths)
Recommended
Dosing
(n ¼ 360 Deaths)
Nonrecommended
High Dosing
(n ¼ 33 Deaths)
Cardiovascular cause 60 (30.8) 104 (28.9) 9 (27.3)
Congestive heart failure 25 (12.8) 37 (10.3) 6 (18.2)
Sudden or unwitnessed death 5 (2.6) 16 (4.4) 1 (3.0)
Myocardial infarction 8 (4.1) 11 (3.1) 0 (0.0)
Nonhemorrhagic stroke 6 (3.1) 11 (3.1) 1 (3.0)
Atherosclerotic vascular disease 3 (1.5) 3 (0.8) 0 (0.0)
Intracranial hemorrhage 1 (0.5) 5 (1.4) 0 (0.0)
Pulmonary embolism 0 (0.0) 5 (1.4) 0 (0.0)
Dysrhythmia 1 (0.5) 2 (0.6) 1 (3.0)
Directly related to revascularization 0 (0.0) 1 (0.3) 0 (0.0)
Other/unknown cardiovascular cause 11 (5.6) 13 (3.6) 0 (0.0)
Noncardiovascular cause 74 (37.9) 171 (47.5) 19 (57.6)
Malignancy 24 (12.3) 60 (16.7) 4 (12.1)
Respiratory failure 11 (5.6) 29 (8.1) 2 (6.1)
Infection 7 (3.6) 17 (4.7) 0 (0.0)
Sepsis 7 (3.6) 14 (3.9) 1 (3.0)
Renal disease 5 (2.6) 5 (1.4) 2 (6.1)
Accidental/trauma 2 (1.0) 8 (2.2) 1 (3.0)
Liver failure 3 (1.5) 2 (0.6) 0 (0.0)
Suicide 0 (0.0) 2 (0.6) 0 (0.0)
Other/unknown noncardiovascular
cause
15 (7.7) 34 (9.4) 9 (27.3)
Other/unknown cause 61 (31.3) 85 (23.6) 5 (15.2)
Values are n (%). *Percentages calculated among the total number of deaths within each dosing group.
TABLE 4 Odds Ratios for Selected Predictors of
Nonrecommended Low Dosing
Predictor OR (95% CI)
Female 1.21 (1.09–1.35)
Age (65 yrs or older), 5-yr increase 1.51 (1.46–1.57)
Ethnicity (reference Caucasian)
Hispanic/Latino 2.17 (1.70–2.76)
Asian 3.16 (2.77–3.59)
Afro-Caribbean/mixed/other 2.07 (1.49–2.88)
Weight (up to 80 kg), 5-kg increase 0.95 (0.92–0.98)
Acute coronary syndrome 1.16 (0.99–1.37)
Vascular disease 1.19 (0.99–1.43)
Prior stroke 0.74 (0.61–0.90)
Diabetes 1.17 (1.03–1.32)
Moderate to severe CKD 0.48 (0.40–0.58)
Concomitant AP therapy 1.26 (1.09–1.45)
AP ¼ antiplatelet; CI ¼ confidence interval; CKD ¼ chronic kidney disease;
OR ¼ odds ratio.
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1433SE and on the primary safety composite endpoint of
major and clinically relevant nonmajor bleeding, but
the trial was underpowered (25). This may explain the
high rate of underdosing of DOACs in Japan (even
when assessed according to Japanese regulations),
but also in Korea and other Asian countries that may
unofficially follow the rules of prescriptions applied
in Japan, despite local SPCs instructing otherwise
(22,26,27). The lowest rates (<20%) of underdosage
were observed chiefly in North America and in Euro-
pean countries except France, Germany, and Spain,
where underdosage ranged from 20% to 30%. Over-
dosage was observed at rates <5%. Strikingly, almost
70% of patients with excessive dosage had moderate-
to-severe renal impairment. The investigators may
have unintentionally disregarded the rules of pre-
scription related to renal function or may have relied
on different rules issued by national or regional
organizations.
In addition, the investigators may not have accu-
rately assessed the risk profile of patients. At base-
line, both underdosed and overdosed patients tended
to be at higher risk of stroke/SE, bleeding, and death
than patients who were on recommended doses, and
the rates of nonrecommended doses increased with
increasing CHA2DS2-VASc scores. The highest-risk
patients were more prone to receive non-
recommended doses of DOACs, perhaps because of
bleeding concerns.
Last, as shown in a recent report, access to high-
quality health care is highly variable between coun-
tries, including those involved in GARFIELD-AF (28).
This may have had an impact on compliance to pre-
scription rules and recommended dosage of
anticoagulants.
The prescription of the recommended doses also
varies with the different products. Prescription ac-
cording to the labeling was more frequently seen for
the DOACs initially marketed, namely dabigatran and
rivaroxaban, whereas higher rates of low dosing were
seen with apixaban and edoxaban (over 50% with this
drug), both of which have been marketed more
recently, and in the case of edoxaban, experience in
GARFIELD-AF was confined mostly to the Japanese
market.
Not surprisingly, age, weight, and moderate-to-
severe CKD were strong predictors of underdosage,
as recommendation of dosage is mainly defined ac-
cording to these 3 variables. Additionally, female sex,
non-Caucasian ethnicity, acute coronary syndrome,
vascular disease, prior stroke, diabetes, and
concomitant AP therapy had a strong effect on the
risk of underdosing. When variables used in the
definition of underdosing were removed fromthe selection procedure, congestive heart failure,
management in office or anticoagulant clinics, and
diastolic blood pressure emerged as strong predictors
of underdosing. The effect of ethnicity is not unex-
pected, as it is a surrogate of the region/country of
enrollment in the registry.
FIGURE 3 Odds Ratios for Selected Predictors of Nonrecommended Low Dosing
Concomitant AP Therapy
Moderate to Severe CKD
Diabetes
Prior Stroke
Vascular Disease
Acute Coronary Syndrome
Weight (Up to 80 kg), 5 kg Increase
Afro-Caribbean/Mixed/Other
Asian
Hispanic/Latino
Ethnicity (Reference Caucasian)
Age (65 Years or Older), 5-Year Increase
Female
0.5 5.03.02.01.51.0
Increases risk of
nonrecommended low dosing
Decreases risk of
nonrecommended low dosing
Odds Ratio
(Ref. Recommended Dosing)
Percentages calculated among the total number of deaths within each dosing group. AP [ antiplatelet; CKD [ chronic kidney disease.
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tries or observational studies (29–31). In the ORBIT-AF
(Outcomes Registry for Better Informed Treatment of
Atrial Fibrillation) registry, the rate of non-
recommended doses was quite low, in the range of
12%, and was associated with poor outcomes, signif-
icantly higher risk of all-cause death in overdosed
patients, and higher rates of cardiovascular rehospi-
talization in underdosed patients. The population of
patients receiving nonrecommended doses was at
higher risk at baseline than patients receiving the
recommended dose. Older age, female sex, and
noncardiologist-treating physicians were the most
important predictors of off-label prescription (30). In
XANTUS (Xarelto for Prevention of Stroke in Patients
With Atrial Fibrillation), a prospective, international,
observational study of patients receiving rivaroxaban
for AF, recommendation of dosing was based on CrCl
assessment. Nonrecommended (higher and lower
than recommended) dosage was significantly associ-
ated with a higher risk of death and of reaching the
composite endpoint of the study (major bleeding,
stroke/SE, and death) than patients with recom-
mended dosage. The excess of risks, including death,
was no longer significant after adjustment, suggest-
ing that the higher rates of events associated with
nonrecommended dosage were more related to
comorbidities than to the dose of the drug and the
comorbidities used for determining the dose (32). In a
more recent report retrospectively reviewingrecommendations of dosing of rivaroxaban and
adherence to dietary requirements, the rate of non-
recommended administration (dosing and/or dietary
requirements) was reported as high as 40%, mostly
when the drug was prescribed by noncardiologists
(33). In the retrospective analysis of patients with
nonvalvular AF that was conducted by OptumLabs,
13.3% of patients had received reduced doses. The
reduced dose of apixaban was associated with a
nearly 5-fold higher risk of stroke and a similar risk of
major bleeding when compared with standard dose of
apixaban (34). The data from three nationwide reg-
istries in Denmark demonstrated that the rates of
ischemic stroke or SE with a reduced dose of apixaban
(2.5 mg) were higher but not significantly different
when compared with warfarin (35).
STUDY STRENGTHS AND LIMITATIONS. The strength
of this study is that dosage recommendations of each
DOAC was carefully assessed on a national/regional
basis, taking into account the Summaries of Product
Characteristics (SPC) of each DOAC issued by EMA (2),
FDA (3), or PMDA (4) depending on the country where
the drug was used. EMA SPCs were used for European
countries, FDA SPCs for Northern America, and PMDA
SPCs for Japan only. For all other countries, we
assumed that EMA rules for prescription as summa-
rized in an European consensus document (18) were
implemented, although some countries may have
their own rules for prescription that may differ from
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
OUTCOMES: In a practice-based registry of patients with
recently detected atrial fibrillation, prescription of non-
recommended doses of target-specific oral anticoagulant
(DOACs) was associated with a higher risk of death, mostly car-
diovascular death, compared with patients prescribed recom-
mended doses.
TRANSLATIONAL OUTLOOK: More pervasive strategies are
needed to promote approved dosing of DOACs.
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1435EMA rules. This is true for South Korea, China, and
India (10,22,26,27,36–41).
By design and according to the requirements of
purely observational registries, renal function
testing was not mandatory, but was reported by the
investigators as CKD defined according to eGFR.
Creatinine clearance is used in the labeling of most
DOACs instead of eGFR according to the National
Kidney Foundation. It is possible that, in some in-
stances, uncertainty over renal function may have
led investigators to unintended overdosing. In
addition, coadministration of drugs with potential
influence on the pharmacokinetics/pharmacody-
namics of the various DOACs, particularly P-glyco-
protein inhibitors, was not captured in the CRF.
Similarly, food–drug interactions that may affect the
pharmacokinetics/pharmacodynamics of certain
DOACs were not captured (33). Treatment discon-
tinuations or changes in dosage over time were also
not considered because of the very complicated na-
ture of discontinuations, interruptions, dosing
changes, and switching between anticoagulants.
However, discontinuation may have had an addi-
tional deleterious impact on outcomes. Outcomes
may have been at least partially influenced by
uncaptured information, although frequent and
prospective data collection and site-audit minimized
this. In addition, because of limited sample sizes, no
firm conclusions can be drawn about overdosage and
about edoxaban. In Austria, Chile, China, Finland,
India, Norway, Switzerland, Singapore, and
Thailand, the number of patients recruited
was <100. The rates of DOAC prescription in these
countries have to be considered with caution.
CONCLUSIONS
In the GARFIELD-AF registry, most patients pre-
scribed DOACs for stroke prevention received therecommended doses according to country-specific
guidelines. The use of nonrecommended doses was
not uncommon and was associated with worse
outcome, namely higher risk of all-cause death,
mostly cardiovascular death, but was not associated
with a significant increased risk of stroke/SE and/or
major bleeding. Treatment above the recommended
doses was relatively rare compared with non-
recommended low dosing. Of those who were treated
over the recommended doses, 67.5% had moderate-to
severe CKD, as opposed to 8.6% of patients with
recommended dosing and 7.1% of patients with
underdosing. The highest-risk patients were more
prone to receive nonrecommended doses of DOACs.
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